Faced with diminishing returns on R&D investments, large pharmaceutical companies are searching for innovative ways to successfully identify, develop, and market products with financial viability. Yet small discovery companies and biotechs continue to outpace large pharma in the approval of NMEs (new molecular entities).
{iframe}http://www.lifescienceleader.com/doc/janssen-pharmaceuticals-r-d-adopts-a-venture-capital-innovation-model-0001{/iframe}